

Computation of Ceiling Price based on Aug 2015 Data under Para 6 of DPCO 2013												
									Number of Companies consisting of Market Share of 1% & Above		1	
6.4.3.2.1	Efavirenz	Capsule 600 mg	Per Capsule						Sum of MAT value considered for price calculation (in Lakhs)		0.95	
									PTR under Consideration		51.27	
									% Reduction with compared to Highest Price (average)		3.55%	
									Reduction as per Monopoly condition		1.82	
									PTR after Reduction		49.45	
									Add : 16% Retailer Margin		7.91	
									Ceiling Price (without local taxes)		57.36	
									WPI Reduction wef 1.4.2016 @ -2.7105%		1.55	
									Final Ceiling Price (without local taxes)		55.81	
S.O. 619(E) dated 26.02.2015												
Ceiling Price as per NLEM 2011				61.79		Per Capsule						
Derived Ceiling PTR				53.27								
A. List of Item Under consideration									TOTAL MAT		95,356	
S. No.	Unique No. as per NLEM	Composition as per NLEM	पैक विवरण Pack Description	छाप BRAND	कंपनी Company	Strength	Pack Size	Unit	PTR (Rs.)	MAT (Rs.)	MAT (%)	Price per Unit Considered (Rs.)
1	6.4.3.2.1	EFAVIRENZ J5B6	VIRANZ 600 MG CAPSULE 30	VIRANZ	VERITAZ HEALTHCARE LTD	600 MG	30	CAPSULE	1,538.00	95,356	100%	51.27
B. Computation of Average rate of Reduction under Monopoly												
	S. No.	Drug(s)	Strength	Description	Route of Administration/ Dosage Form & packsize/packaging, if any	S.O. number & date				Reduction with reference to the highest PTR under NLEM 2015 (%)		
	1	Efavirenz	600 mg tablet		Tablet	2729(E) dated 17.8.2016				3.55		
									Average Reduction		3.55	

Computation of Ceiling Price based on Aug 2015 Data under Para 6 of DPCO 2013												
									Number of Companies consisting of Market Share of 1% & Above		1	
10.1.4	Folic acid	Capsule 5 mg	Per Capsule						Sum of MAT value considered for price calculation (in Lakhs)		23.78	
									PTR under Consideration		5.33	
									% Reduction with compared to Highest Price (average)		12.98%	
									Reduction as per Monopoly condition		0.69	
									PTR after Reduction		4.64	
									Add : 16% Retailer Margin		0.74	
									Ceiling Price (without local taxes)		5.38	
									WPI Reduction wef 1.4.2016 @ -2.7105%		0.15	
									Final Ceiling Price (without local taxes)		5.23	
A. List of Item Under consideration												
									TOTAL MAT		23,78,275	
S. No.	Unique No. as per NLEM	Composition as per NLEM	पैक विवरण Pack Description	छाप BRAND	कंपनी Company	Strength	Pack Size	Unit	PTR (Rs.)	MAT (Rs.)	MAT (%)	Price per Unit Considered (Rs.)
1	10.1.4	FOLIC ACID B3A4	AFOL 5 MG CAPSULE 10	AFOL	LINCOLN PHARMACEUTICALS LTD	5 MG	10	CAPSULE	53.26	23,78,275	100%	5.33
B. Computation of Average rate of Reduction under Monopoly												
	S. No.	Drug(s)	Strength	Description	Route of Administration/ Dosage Form & packsize/packaging, if any	S.O. number & date					Reduction with reference to the highest PTR under NLEM 2015 (%)	
	1	Folic Acid	5 mg		Tablet	1819 (E) dated 18.5.2016					12.98	
									Average Reduction		12.98	

Computation of Ceiling Price based on Aug 2015 Data under Para 6 of DPCO 2013												
										Number of Companies consisting of Market Share of 1% & Above		1
2.1.4	Mefenamic acid	Tablet 500 mg	Per Tablet							Sum of MAT value considered for price calculation (in Lakhs)		443.44
										PTR under Consideration		2.15
										% Reduction with compared to Highest Price (average)		6.67%
										Reduction as per Monopoly condition		0.14
										PTR after Reduction		2.01
										Add : 16% Retailer Margin		0.32
										Ceiling Price (without local taxes)		2.33
										WPI Reduction wef 1.4.2016 @ -2.7105%		0.06
										Final Ceiling Price (without local taxes)		2.27
A. List of Item Under consideration												
										TOTAL MAT	4,46,49,260	
S. No.	Unique No. as per NLEM	Composition as per NLEM	पैक विवरण Pack Description	छाप BRAND	कंपनी Company	Strength	Pack Size	Unit	PTR (Rs.)	MAT (Rs.)	MAT (%)	Price per Unit Considered (Rs.)
1	21.1.4	MEFENAMIC ACID M1A46	MEFTAL 500 MG TABLET 10	MEFTAL	BLUE CROSS LABORATORIES LTD	500 MG	10	TABLET	21.51	4,43,44,320	99.32%	2.15
2	21.1.4	MEFENAMIC ACID M1A46	ALMEFKEM 500 MG TABLET 10	ALMEFKEM	ALKEM LABORATORIES LTD.	500 MG	10	TABLET	11.00	29,832	0.07%	Not Qualified
3	21.1.4	MEFENAMIC ACID M1A46	OSRA 500 500 MG TABLET 10	OSRA 500	BENNET PHARMACEUTICALS LIMITED	500 MG	10	TABLET	16.00	1,34,352	0.30%	Not Qualified
4	21.1.4	MEFENAMIC ACID M1A46	PONSTAN 500 MG TABLET 10	PONSTAN	PFIZER LTD	500 MG	10	TABLET	38.50	1,40,756	0.32%	Not Qualified
B. Computation of Average rate of Reduction under Monopoly												
S. No.	Drug(s)	Strength	Description	Route of Administration/ Dosage Form & packsize/packing, if any	S.O. number & date	Reduction with reference to the highest PTR under NLEM 2015 (%)						
1	Mefenamic Acid	100 mg/5ml		Oral Liquid	1561 (E) dated 27.4.2016	6.67						
						Average Reduction	6.67					

Computation of Ceiling Price based on Aug 2015 Data under Para 6 of DPCO 2013												
									Number of Companies consisting of Market Share of 1% & Above		1	
2.1.4	Mefenamic acid	Tablet 250 mg	Per Tablet						Sum of MAT value considered for price calculation (in Lakhs)		538.79	
									PTR under Consideration		1.69	
									% Reduction with compared to Highest Price (average)		6.67%	
									Reduction as per Monopoly condition		0.11	
									PTR after Reduction		1.58	
									Add : 16% Retailer Margin		0.25	
									Ceiling Price (without local taxes)		1.83	
									WPI Reduction wef 1.4.2016 @ -2.7105%		0.05	
									Final Ceiling Price (without local taxes)		1.78	
A. List of Item Under consideration										TOTAL MAT	5,38,83,712	
S. No.	Unique No. as per NLEM	Composition as per NLEM	पैक विवरण Pack Description	छाप BRAND	कंपनी Company	Strength	Pack Size	Unit	PTR (Rs.)	MAT (Rs.)	MAT (%)	Price per Unit Considered (Rs.)
1	21.1.4	MEFENAMIC ACID M1A46	MEFTAL 250 MG TABLET 10	MEFTAL	BLUE CROSS LABORATORIES LTD	250 MG	10	TABLET	16.90	5,38,79,273	99.99%	1.69
3	21.1.4	MEFENAMIC ACID M1A46	PONSTAN 250 MG TABLET 10	PONSTAN	PFIZER LTD	250 MG	10	TABLET	15.63	4,439	0.01%	Not Qualified
B. Computation of Average rate of Reduction under Monopoly												
S. No.	Drug(s)	Strength	Description	Route of Administration/ Dosage Form & packsize/packing, if any	S.O. number & date	Reduction with reference to the highest PTR under NLEM 2015 (%)						
1	Mefenamic Acid	100 mg/5ml		Oral Liquid	1561 (E) dated 27.4.2016	6.67						
Average Reduction						6.67						

डीपीसीओ 2013 के पैरा 4 के तहत, अगस्त 2015 के आंकड़ों के आधारित, मूल्य की संगणना																
Computation of Ceiling Price based on Aug-2015 Data under Para 4 of DPCO 2013																
									Number of Companies consisting of Market Share of 1% & Above						2	
6.2.2.4	Co-trimoxazole [Sulphamethoxazole (A) +	Oral liquid 200 mg (A) + 40 mg (B)/5 ml	Per ML						Sum of MAT value considered for price calculation						1,106.51	
									Sum of PTR per unit considered for price calculation						0.71	
									Number of Packs considered						4	
									Average PTR						0.18	
									Add : 16% Retailer Margin						0.03	
									Ceiling Price (without local taxes)						0.21	
									% Reduction as compared to Highest Price						21.74%	
									WPI Reduction wef 1.4.2016 @ -2.7105%						0.01	
									Final Ceiling Price (without local taxes)						0.20	
															Minimum Price (Rs.)	0.10
									S.O. 840(E) dated 25.3.2015						Maximum Price (Rs.)	0.23
									Ceiling Price as per NLEM 2011 (wef. 01.4.2015)	0.29	Per ML				Average of all considered (Rs.)	0.18
									Derived Ceiling PTR	0.25					Ceiling Price (Rs.)	0.21
									TOTAL MAT	11,06,67,986					100%	
S. No.	Unique No. as per NLEM	Composition as per NLEM	पैक विवरण Pack Description	छाप BRAND	कंपनी Company	Strength	Pack Size	Unit	PTR (Rs.)	MAT (Rs.)	SKU wise MAT %	Brandwise MAT (ignoring 0% MAT)	Qualify (Y/N) Y=Yes N=No	Price per Unit (Rs.)	Price per Unit (Rs.) Considered	
1	6.2.2.4	TRIMETHOPRIM COMBINATIONS J1E1	ANTRIMA SUSPENSION 50 ML	ANTRIMA	ABBOTT HEALTHCARE PVT. LTD	200/40 MG	50	ML	10.82	16,977	0.02%	0.02%	N	0.22		
2		TRIMETHOPRIM COMBINATIONS J1E1	BACTRIM SYRUP 50 ML	BACTRIM	ABBOTT HEALTHCARE PVT. LTD	200/40 MG	50	ML	11.72	2,93,85,913	26.55%	26.55%	Y	0.23	0.23	
3		TRIMETHOPRIM COMBINATIONS J1E1	SEPTRAN PEAD 200/40 MG SUSPENSION 100 ML	SEPTRAN	GLAXOSMITHKLINE PHARMACEUTICALS LTD.	200/40 MG	100	ML	10.34	7,98,470	0.72%	73.43%	Y	0.10	0.10	
4		TRIMETHOPRIM COMBINATIONS J1E1	SEPTRAN PEAD 200/40 MG SUSPENSION 60 ML	SEPTRAN	GLAXOSMITHKLINE PHARMACEUTICALS LTD.	200/40 MG	60	ML	10.34	72,57,757	6.56%	73.43%	Y	0.17	0.17	
5		TRIMETHOPRIM COMBINATIONS J1E1	SEPTRAN PEAD 200/40 MG SUSPENSION 50 ML	SEPTRAN	GLAXOSMITHKLINE PHARMACEUTICALS LTD.	200/40 MG	50	ML	10.34	7,32,08,869	66.15%	73.43%	Y	0.21	0.21	

Computataion of Retail Price based on Nov., 2015 Data under Para 4 of DPCO 2013													
Clobetasol Propionate IP 0.05% w/w + Neomycin Sulphate IP 0.50% w/w + Clorimazole IP 1.00% w/w + Chlorocresol 0.1% IP cream of M/s Pharma Focus Labs./ M/s Mankind Pharma													
							Number of Companies consisting of Market Share of 1% & Above					3	
							Sum of MAT value considered for price calculation (in Lakhs)					1,300.16	
							Sum of PTR per unit considered for price calculation					7.87	
							Number of Packs considered					3	
							Average PTR					2.62	
							Add : 16% Retailer Margin					0.42	
							Retail Price (without local taxes)					3.04	
							% Reduction with compared to Highest Price					19.38%	
												Minimum Price (Rs.)	1.83
												Maximum Price (Rs.)	3.25
												Average of all considered (Rs.)	2.62
												Retail Price (Rs.)	3.04
							TOTAL MAT	13,04,48,930	100%				
S. No.	Pack Description	BRAND	Company	Strength	Pack Size	Unit	PTR (Rs.)	MAT (Rs.)	SKU wise MAT %	Qualify (Y/N) Y=Yes N=No	Price per Unit (Rs.)	Price per Unit (Rs.) Considered	
1	CLOP GM NEO CREAM 15 GM	CLOP GM NEO	ZYDUS CADILA	1/0.05/0.5 %W/W	15	GM	41.87	8,67,05,385	66.47%	Y	2.79	2.79	
2	CLOSTAR-GM 1/0.05/0.5 %W/W CREAM 16 GM	CLOSTAR-GM	MANKIND PHARMACEUTICALS LTD.	1/0.05/0.5 %W/W	16	GM	29.33	3,97,50,912	30.47%	Y	1.83	1.83	
3	CLOBEATE GM CREAM 10 GM	CLOBEATE GM	RANBAXY LABORATORIES LTD	1/0.05/0.5 %W/W	10	GM	9.90	84,658	0.06%	N	0.99		
4	TRIBEN CN CREAM 15 GM	TRIBEN CN	JENBURKT PHARMACEUTICALS LTD	1/0.05/0.5 %W/W	15	GM	48.76	35,60,190	2.73%	Y	3.25	3.25	
5	ZINCORT GC NEO 1/0.05/0.5 % CREAM 15 GM	ZINCORT GC NEO	MEGHA HEALTHCARE	1/0.05/0.5 %W/W	15	GM	37.34	3,47,785	0.27%	N	2.49		